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Edited by Ga´spa´r Je´kelyAbstract Endocytosis is a versatile tool to regulate the inten-
sity, localization, half-life and function of signaling complexes
(signalosomes) that form in cells upon binding of growth factors,
cytokines and morphogens to their cognate receptors. Endocytic
adaptors are non-catalytic proteins that assemble eﬀectors and
structural components of the endocytic machinery around the
traﬃcking cargo and serve as scaﬀolds for signalosomes, which
in turn modify their location and activity by various post-trans-
lational modiﬁcations. We discuss how breakdowns in the func-
tion of endocytic adaptors might facilitate impairment of tissue
homeostasis and consequent tumor development.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Appropriate growth, morphogenesis and homeostasis of tis-
sues in multicellular organisms depend on tightly regulated cel-
lular responses to growth factors, cytokines and morphogens.
Upon binding of these ligands to their cognate transmembrane
receptors, a vast repertoire of highly dynamic protein com-
plexes (signalosomes) is assembled inside the cell, which ampli-
fy the signal and ultimately transduce it into changes in the
proteome and genome status. This has been traditionally de-
picted as signaling pathways of transducers, second messengers
and eﬀectors [1]. Cells can bind to diﬀerent ligands simulta-
neously and the same ligand can elicit many outputs in the
same or in diﬀerent cell types depending on which, where
and for how long signalosomes are formed and on their ability
to interact with components of other signaling pathways. How
is the speciﬁcity of action achieved by signalosomes, how is
their location and half-life regulated and how they propagate
a signal from the plasma membrane to the nucleus are some
of as yet open questions.
Insights into these issues have come from extensive molecu-
lar characterization of the endocytic machinery. Endocytosis is
a widely conserved process in eucaryotes by which cells ‘‘eat’’
extracellular particles (phagocytosis) or ‘‘drink’’ extracellular
ﬂuids (pinocytosis). It is usually classiﬁed as ligand-dependent*Corresponding author.
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doi:10.1016/j.febslet.2005.03.029or independent (constitutive), and in turn either clathrin-med-
iated or not [2,3]. Because transmembrane proteins cannot
redistribute to the cytosol for obvious chemical reasons, they
have to be internalized and degraded together with the lipid bi-
layer in order to regulate their number at the cell surface. In
the case of receptors, this is required for prolonged desensitiza-
tion of cells to extracellular stimuli such as growth factors and
cytokines [4]. To achieve this goal and counterbalance, the
addition of new membrane to the cell surface by exocytosis,
endocytosis has been selected throughout the evolution of
eucaryotes as a compelled route that transmembrane proteins
have to follow to enter the cell. For a long time, the role of
endocytosis in signal transduction has been viewed merely as
a way to internalize and degrade (downregulation) activated
transmembrane receptors, thus terminating signaling [5]. How-
ever, growing evidence suggests a closer and more complex
relationship between endocytosis and signaling [6]. At least
in the case of receptors for epidermal and nerve growth factor,
it has been clearly shown that receptor-containing signalo-
somes are still active while traﬃcking along the endocytic
route, though the output may be diﬀerent. In turn, signalo-
somes control the activity of the endocytic machinery by
post-translational modiﬁcations such as phosphorylation or
ubiquitylation, thus inﬂuencing their own fate [6,7]. Endocytosis
may be even necessary to activate transmembrane receptors, as
in the case of Notch [2]. Lastly, traﬃcking ligand-bound recep-
tors can escape degradation and return to the plasma mem-
brane through specialized endocytic organelles known as
recycling endosomes. Variations in the balance between
degradation versus recycling endocytic pathways create mor-
phogen gradients important in tissue patterning during devel-
opment [2,6].
Thus, it appears that endocytic organelles (endosomes) also
contribute to the ampliﬁcation and propagation of extracellu-
lar signals [8]. Various kinds of endosomes can be recognized
along the endocytic route exhibiting a rich mosaic composition
in lipid and proteins [9]. In analogy to metabolism, this high
degree of compartmentalization is likely to be very important
in the temporal and spatial regulation of signalosomes, and to
account for the speciﬁcity of the cell response to growth fac-
tors, cytokines and morphogens [8,10]. Hence, it has been pro-
posed that breakdowns in the endocytic machinery might be
oncogenic by perturbing the duration and speciﬁcity of signal-
ing events that control tissue growth, morphogenesis and
homeostasis. Here, we discuss recent experimental evidences
supporting this hypothesis with special focus on endocytic
adaptor proteins.blished by Elsevier B.V. All rights reserved.
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In a mechanistic view, receptor endocytosis can be de-
scribed as a highly sophisticated machinery that speciﬁcally
recognizes a receptor cargo at the plasma membrane, then
internalizes and transports it inside the cell and lastly sorts
it either for recycling back to the cell surface or for degrada-
tion in lysosomes. In the last decade, a bulk of experimental
data has shed light onto the molecular components of the
endocytic machinery, showing us a few fundamental princi-
ples. Firstly, the information that regulates internalization
and traﬃcking of receptors can be stored in their primary
structure or derive from post-translational modiﬁcations of
their cytosolic tails, such as phosphorylation and ubiquityla-
tion [11]. Secondly, the membrane of endocytic organelles
(endosomes) is a dynamic mosaic of lipid domains which re-
cruit diﬀerent repertoires of endocytic proteins. These can in
turn modify the lipid composition of the domain they interact
with [9]. Third, like in signal transduction or metabolic path-
ways, a functional hierarchy seems also to exist in the endo-
cytic machinery. Structural molecules, such as clathrin or
lipids, are instructed to assemble in highly ordered and dy-
namic modules such as coated-pits or membrane microdo-
mains by eﬀectors endowed with enzymatic properties.
These also mediate movements of endosomes along microtu-
bules and the actin cytoskeleton. The activity of eﬀectors is in
turn tightly controlled by regulatory proteins or protein do-
mains. Lastly, the cargo and each component of the endo-
cytic machinery are connected by adaptor proteins. Using a
metaphor, the cytoskeleton is the road, endosomes are the
car, regulatory proteins the driver, eﬀectors the engine and
adaptors the bolts.
Canonically, adaptors have been deﬁned as proteins with
domains for protein–protein or protein–lipid interaction, sites
for inducible post-translational modiﬁcations and lacking cat-
alytic activity [4]. A subgroup of adaptors, also known as scaf-
folds, like Cbl and CIN85, can assemble macromolecular
complexes by binding to many other proteins and to them-
selves simultaneously. Adaptors have been found to play crit-










Fig. 1. Three major mechanisms how oncogenic transformation can be media
and internalization of receptor tyrosine kinases can result in increased sig
signaling from endosomes. Chromosomal translocations can produce artiﬁcia
leading to loss of transcriptional control. Such changes in cellular signalingand cytokine receptors. In signaling, they are required for
the assembly of complexes containing activated receptors,
eﬀectors and regulators (signalosomes). In endocytosis, they
are necessary to select and sort the receptor cargo either for
degradation or recycling and to connect endocytic eﬀectors
and regulators to endosomes and to the cytoskeleton. Endo-
cytic adaptors may also contribute to specify the composition
of signalosomes while they travel along the endocytic route.
Thus, adaptors are the junction ring between signaling and
endocytosis.3. Dysfunction of endocytic adaptors can lead to cancer
Receptor tyrosine kinases (RTK) form a large family of
transmembrane receptors for growth factors and morphogens
that have been widely implicated in human and experimental
cancers. This can occur through ampliﬁcation, point mutations
or deregulated gene expression, resulting in ligand-independent
activation and oncogenic conversion of receptors [12]. How-
ever, since the molecular details of RTK endocytosis began
to be unraveled, additional mechanisms have been put forward
to explain how these and other receptors, e.g., those for cyto-
kines, may be involved in cancers. Alteration of signals for
sorting transmembrane proteins to lysosomes, especially in
the context of constitutively active RTK, may contribute to
the progression of some neoplasms, if not be the initiating
event. For example, escape from Cbl-mediated downregula-
tion is a recurrent theme in oncogenic deregulation of RTK
[13]. Cbl proteins form a family of non-canonical scaﬀolds that
can bind to more than a hundred partners and have ubiquitin
ligase activity [4,5,14]. Upon ligand stimulation, Cbl binds to
speciﬁc phosphotyrosine-based motifs in the juxtamembrane
region of RTK through its phosphotyrosine-binding domain
(PTB). Loss of PTB-mediated Cbl binding is found in several
oncogenic variants of EGFR, c-Met, CFS-1R and c-Kit [13].
The machinery that tags RTK and other transmembrane
receptors for internalization and endosomal sorting can be al-










ted by changes in the cellular transport machineries. Defects in sorting
naling, whereas changes of endocytic adaptors may speciﬁcally alter
l fusion proteins of endocytic adaptors with transcriptional regulators,
are likely to result in oncogenic transformation of the cells.
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expression of the Cbl-related protein Hakai, an E3 ligase for E-
cadherin, causes cell scattering in vitro [15], and hyper-phos-
phorylation of Hakai by constitutively active oncogenic
RTK may reduce the amount of E-cadherin at the cell surface,
thus contributing to invasiveness [16]. Several reports have
indicated that the adaptor proteins required for appropriate
receptor downregulation play distinct roles in oncogenesis.
We highlight three fundamental mechanisms by which this
can occur: normal RTK or their oncogenic counterparts are
internalized or degraded to a lesser extent, due to defects of
the internalization/sorting machinery; signaling from endo-
somes is qualitatively and/or quantitatively altered, mainly as
a consequence of aberrantly functioning endocytic adaptors;
generation of fusion proteins between endocytic adaptors
and regulatory proteins is commonly found in several hemato-
logical malignancies (Fig. 1).4. In fugue from lysosomes
HIP1 was the ﬁrst endocytic adaptor to be found overex-
pressed in many cancers, including breast, prostate and co-
lon cancers. In prostate cancer, HIP1 levels correlate with
histotype and grade at diagnosis and predict a poor clinical
outcome [17]. HIP1 was found in a yeast-two-hybrid screen
as a novel protein that interacts with the N-terminal domain
of Huntingtin, the product of the Huntington Chorea gene.
HIP1 and its related homologue HIP1R (also HIP12) share
a central coil-coiled domain, an epsin N-terminal homology
domain (ENTH) which binds to PtdIns(4;5)P2 and a talin-
like domain at the carboxyl terminal required for binding
to F-actin [18–20]. ENTH domains are also found in other
adaptors required to assemble clathrin coats, such as amphi-
physins, epsin-1/-2 and AP180/CALM. Indeed, both HIP1
and HIP1R promote clathrin assembly in vitro by binding
to the highly conserved 22 amino acid sequence in clathrin
light chains [21,22]. Paradoxically, when stably overexpres-Table 1
Examples of endocytic adaptors and their alterations implicated in oncogen
Protein Transforming ability Alter
Hip1 NIH3T3, overexpression Overe
Fusio
Tsg101 NIH3T3, knock-out Short
Overe
Numb No evidence Lost
Intersectin NIH3T3, overexpression No e
PML No evidence Fusio
Clathrin No evidence Fusio
Fusio
AP-180/CALM No evidence Fusio
Fusio
Eps15 NIH3T3, overexpression Fusio
Endophilin II (EEN) No evidence Fusiosed in mouse NIH3T3 ﬁbroblasts, instead of promoting
clathrin-dependent endocytosis, HIP1 dramatically decreases
the internalization rate of epidermal growth factor receptors
(EGFR). This results in a strong activation of the MAPK
and PI3K signaling modules, cell transformation and tumor-
igenicity in nude mice. Interestingly, overexpression of HIP1
in NIH3T3 cells reduces the intracellular levels of the clath-
rin adaptor AP2 and causes relocalization of clathrin to the
perinuclear region, suggesting that the removal of clathrin
from the plasma membrane might explain the defect in
EGFR internalization [24]. A further level of complexity
has come from the ﬁnding that RNAi-mediated knock-down
of HIP1R results in a stable association between the endo-
cytic and the actin-assembling machineries [25]. Hence, while
it is clear that overexpression of HIP1 is oncogenic, the ex-
act mechanism for this eﬀect still remains open for future
investigations. Eps15, another endocytic adaptor implicated
in EGF receptor internalization and endocytosis can also
cause cell transformation when overexpressed in NIH3T3
ﬁbroblasts [23], indicating that disturbance in several adap-
tor proteins in the endocytic pathway may have a similar
outcome (Table 1).
Another endocytic adaptor, namely the product of the Tu-
mor-Suppressor Gene 101 (Tsg101), has been extensively stud-
ied for its potential role in oncogenesis. Tsg101 was identiﬁed
in a random insertional mutagenesis screen for tumor suppres-
sors in NIH 3T3. Knock-out of Tsg101 in NIH3T3 ﬁbroblasts
induces in vitro transformation and metastatic tumors when
these cells are injected subcutaneously into nude mice [26].
Interestingly, Tsg101 maps at 11p15, a region with frequent
loss-of-heterozygozity (LOH) in breast, ovarian, testicular
and Wilms cancers, suggesting that it might truly function
as an onco-suppressor. A further hint of Tsg101 involvement
in human oncogenesis came soon after its discovery from the
observation that it interacts with the regulator of cell growth
and diﬀerentiation oncoprotein18/stathmin, which is overex-
pressed in some acute leukemias and in neuroblastoma [27].
Under normal conditions, Tsg101 is recruited from the cytosol
to the membrane of late endosomes, where it together withesis
ations in human cancer Oncogenic mechanism
xpression Blocks EGFR endocytosis
n with PDGFR Constitutively active PDGFR
spliced transcripts Uncertain
xpression Uncertain
in breast cancer Cell division?
vidence No evidence
n with RAR-alpha Blocks apoptosis
n with TFE3 Clathrin sequestered?
n with ALK ALK constitutively active
n with AF10 Dominant-negative on CALM?
n with MLL Dominant-negative on CALM
n with MLL Oncogenic conversion
n with MLL Sequestration of EBP?
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sorting of ubiquitylated endocytic cargos into the inner vesicles
of MVB. The crucial importance of Tsg101 in sorting cargos
for lysosomal degradation is highlighted by the ﬁnding that
its inactivation by speciﬁc antibody microinjection into the
cytosol blocks EGFR degradation and increases its recycling
[28]. It was proposed that inhibition of Tsg101 function will
lead to a block in RTK sorting and subsequent accumulation
of active receptors in endosomes, which may lead to the aber-
rant endosomal signaling implicated in tumor development.
However, although these results strongly suggest a potential
role of Tsg101 as a tumor suppressor, there is so far no clear
proof for this. Initial detection by RT-PCR of large intragenic
deletions responsible for the expression of short Tsg101 tran-
scripts in primary breast carcinomas [27] has been subse-
quently disproven by Southern blot [29]. Though short
Tsg101 mRNA variants have been detected in a large variety
of human cancers, including SCLC [30], ovarian and breast
cancers [31], sarcomas [32], leukemia and lymphomas [33], cer-
vical and endometrial cancers [34], as well as in many tumor
cell lines, the same short transcripts have also been found in
normal tissues. Moreover, in none of these cases gene dele-
tions, point-mutations or rearrangements were found at the
Tsg101 locus, and the short transcripts were actually alterna-
tive spliced variants [35,36]. Moreover, knock-out of Tsg101
in mouse mammary gland does not result in breast cancer for-
mation. Complete Tsg101 knock-out is embryonic lethal, while
heterozygous mice or mammary gland-speciﬁc knock-out mice
show impaired mammogenesis during late pregnancy [37].
Alternatively, Tsg101 could be oncogenic independently of
its function in endocytosis. Indeed, it has been recently demon-
strated that the Tsg101 product controls the levels of the E3
ubiquitin ligase MDM2. Upregulation of Tsg101 inhibits deg-
radation of MDM2, thus enhancing poly-ubiquitylation and
proteasomal degradation of the p53 gene product [38]. In con-
clusion, the endocytic adaptor Tsg101 seems to participate in
human oncogenesis, but further studies should be undertaken
to investigate the impact of Tsg101 overexpression on RTK
endocytosis before any deﬁnite conclusion is drawn.
An interesting example of an endocytic adaptor involved in
oncogenesis is Numb. The numb gene was originally identiﬁed
in Drosophila as a mutant that causes cells of the sensory organ
precursor (SOP) to fail in diﬀerentiating into peripheral sen-
sory neurons [39]. A strikingly similar phenotype is seen when
the ear domain of the clathrin adaptor AP2 is mutated in Dro-
sophila and cannot bind anymore to other endocytic proteins
such as Eps15, epsins, amphiphysin and dynamin. A role of
Numb in endocytosis has been suggested due to the observa-
tions that it partially colocalizes with AP2 and Eps15 in clath-
rin-coated pits and early endosomes [40] and physically
interacts with them in vivo [41]. Moreover, deleted forms of
Numb act in a dominant-negative manner over wild-type
Numb and inhibit EGF and transferrin receptor internaliza-
tion. Recently, Numb has also been shown to interact with
the clathrin-independent endocytic protein Arf6 and to play
a role in recycling of receptors to the plasma membrane [42].
Interestingly, Numb is found in complex with the ear domain
of AP2 and Notch receptors and this interaction is required for
receptor internalization [43]. The Notch family comprises a
variety of transmembrane receptors that are crucial to control
cell-fate determination and stem cell self-renewal during devel-
opment and in adult tissues [44]. In dividing Drosophila SOPcells, Numb is asymmetrically distributed and this in turn
causes asymmetrical partitioning of AP2. In this way, one
daughter cell receives a full complement of Numb and AP2
and can downregulate Notch, while the other daughter cell ex-
presses high levels of Notch, which promote its diﬀerentiation
along a diﬀerent lineage. During the development of Drosoph-
ila sensory organ, binary decisions of this sort lead to the for-
mation of ﬁve diﬀerent cell types and ablation of Numb
completely impairs this process [45]. In 50% of primary breast
human carcinomas immunoreactivity against Numb was lost
as a consequence of its ubiquitylation and proteasomal degra-
dation. In these Numb-negative tumors, Notch signaling was
enhanced and reverted to basal levels upon overexpression of
Numb. On the other hand, knock-down of Numb using the
siRNA technique increased Notch signaling in normal breast
cells and Numb-positive breast cancers [46]. This study indi-
cated a novel paradigm of the role of Notch signaling deregu-
lation in cancer: in addition to constitutive activation or
overexpression described in a large variety of human tumors
[44], also impairment of Notch receptors endocytosis may be
oncogenic.5. Mad signaling from endosomes
Endocytic organelles (endosomes) contribute to the ampli-
ﬁcation and propagation of extracellular signals [8]. For in-
stance, it has been shown that receptor endocytosis is
required for the activation of the MAPK pathway, at least
in the case of epidermal growth factor receptor. Some endo-
cytic adaptors can work as platforms on which speciﬁc sig-
nalosomes can be assembled to function along the
endocytic route. For example, the recently identiﬁed late
endosomal protein p14 recruits the MAPK scaﬀold MP1
and is required for Erk-1/-2 activation during the late signal-
ing phase following RTK stimulation [47]. It seems therefore
reasonable to predict that overexpression, ablation or muta-
tion of endocytic adaptors that allows signaling from endo-
somes may be oncogenic. Indeed, a hint that this might be
the case comes from the scaﬀold intersectin, another adaptor
that connects signaling to endocytosis. Members of the evolu-
tionary conserved intersectin family include intersectin,
Dap160, Ese1/2 and EHSH1, all sharing two N-terminal
EH domains, a central coiled-coil domain followed by three
C-terminal SH3 domains. Intersectin localizes at clathrin-
coated pits, where it binds to AP2, clathrin, dynamin,
Eps15, epsins and synaptojanin. Intersectin also binds to
Sos via its SH3 domains. A C-terminally extended isoform
has been found in the brain and additionally contains DH,
PH, C2 domains, suggesting that it might be a GEF for
Rho GTPases [48]. Overexpression of wt intersectin blocks
transferrin endocytosis [49], but its exact role in clathrin-
dependent endocytosis is still an open question. Upon overex-
pression, intersectin potently activates Elk-1 through a JNK-
dependent but Erkin-dependent pathway, and this eﬀect is
synergized by EGF stimulation [50,51] Interestingly, overex-
pression of intersectin in NIH3T3 ﬁbroblasts results in cell
transformation and depends on an intact EH domain, which
is suﬃcient for JNK activation. On the other hand, the iso-
lated SH3 domains of intersectin partially inhibit EGFR-
induced cell transformation [50], probably due to a
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transforming ability of intersectin may involve Ras along
with JNK, its transforming activity is weak as compared to
H-Ras, and up to now there is no evidence that intersectin
is overexpressed in human cancers, therefore calling for
experimental work in this direction.
In some instances, the signaling output depends on the endo-
cytic route followed by transmembrane receptors. Tranform-
ing growth factor-b receptors (TGFb-R) are a family of
transmembrane Ser/Thr kinases involved in the control of a
plethora of biological functions, including apoptosis and dif-
ferentiation [52]. Upon binding to their cognate ligands,
TGFb-R are rapidly internalized and subsequently downregu-
lated in a ubiquitin-dependent manner [52]. Very interestingly,
clathrin-dependent endocytosis seems to be required for
appropriate TGFb signaling, while internalization through
caveolae is followed by recruitment of the Smad7–Smurf2
complex and rapid receptor degradation [53], though this issue
is still debated. The adaptor SARA (Smad Anchor for Recep-
tor Activation) binds to phosphatidyl-inositol-3-phosphate,
enriched in EEA-1 and Rab5 positive endosomes, and to acti-
vated TGFb receptors. By means of its Smad-Binding Do-
main, SARA also interacts with Smad2 and Smad3 and this
complex is necessary for TGFb signaling from endosomes
[53,54]. Recently, the cytosolic fraction of the product of the
pro-myelocytic leukemia gene (PML) has also been found to
physically interact with SARA and to be present in the
TGFb-RI–TGFb-RII–SARA–Smad complex on early endo-
somal membranes [55]. In acute promyelocytic leukemias
(APL), PML is fused to the retinoic acid receptor RARa as
a consequence of the chromosomal translocation
t(15;17)(q22;q12). In Pml/ mouse embryonic ﬁbroblasts
(MEF), transcription of TGFb-responsive genes was defective
and cells failed to undergo apoptosis upon TGFb treatment.
Expression of cytoplasmic PML (cPML) in the same cells fully
rescued TGFb-mediated transcriptional activity, apoptosis
and cell proliferation arrest [55]. Very interestingly, APL blasts
display very similar defects in TGFb response as Pml/
MEF. In APL, the PML-RARa chimaeric protein is found
both in the nucleus and in the cytosol, where it can dimerize
with the wild-type protein thereby blocking its function. In-
deed, treatment of APL cells with retinoic acid led to degrada-
tion of the PML-RARa fusion and rescued the interaction
between cPML and Smad2/3, resulting in TGFb responsive-
ness [55]. Though the exact function of cPML in clathrin-
dependent endocytosis has to be fully elucidated, these ﬁndings
provide the ﬁrst example of an endocytic adaptor molecule
whose loss-of-function can lead to cancer, by impairing signal-
ing from endosomes. Importantly, PML is frequently lost in
many cancers other than APL, in which an impairment of
TGFb responses has been documented [56]. It will be very
interesting to assess if SARA is also mutated in human cancers
and whether some mutations aﬀect its binding to PML.6. Dangerous partners
Generation of chimaeric proteins following chromosomal
rearrangements is a common pathogenetic mechanism in
the majority of hematological malignancies, especially acute
leukemias. One of the fusion partners is usually a transcrip-
tion factor or a signaling molecule, which functions qualita-tively and/or quantitatively diﬀerently in the context of the
chimaera as compared to the normal counterpart. In some
cases, the chimaeric protein can display a dominant-negative
eﬀect on the normal protein, as described above for PML-
RaRa. The MLL gene encodes a histone methyl-transferase,
part of a supercomplex that regulates the transcription of sev-
eral genes including Hox family members [57]. It is mutated
in 10% of adult and 80% of child acute leukemias. MLL
has been found fused to more than 50 partners as a result
of chromosomal translocations. The resulting chimaeric pro-
teins are thought to be oncogenic via the acquisition of het-
erologous transcriptional eﬀector domains by MLL [58].
However, in some cases MLL fuses with cytoplamic proteins
with no transcriptional function. One example is the EGF
receptor substrate 15 (Eps15), which is fused to MLL in
the rare non-random translocation t(1;11)(p32;q23), resulting
in a MLL-Eps15 chimaeric protein that retains the DNA-
binding domains of MLL [59]. Eps15 is an endocytic adaptor
containing three copies of the EH domain, which interacts
with other endocytic proteins, including the aforementioned
Numb and the adaptor CALM/AP180 (see below). Eps15 is
important for ligand-induced EGFR internalization and it
is thought to recruit ubiquitylated receptors to either to cave-
loae pathway or clathrin-coated pits by binding to ubiquiti-
nated receptors via its UIM motifs or to clathrin and the
clathrin adaptor AP2, respectively [60]. Importantly, Eps15
has a central coiled-coil domain responsible for homo- and
hetero-oligomerization [3,61] and its coiled-coil domain is
necessary and suﬃcient for the Eps15-MLL fusion to be
oncogenic [62]. Dimerization of MLL is likely to create a
transcriptional activator complex, as upon serial plating on
methyl-cellulose the MLL-Eps15 fusion maintains expression
of Hox genes in hematopoietic progenitors, while the MLL
moiety alone does not [62]. Similarly, the rare chronic myel-
omonocytic leukemia translocation t(5;7)(q33;q11.2) fuses the
transmembrane and kinase domains of PDGF receptor
(PDGFR) b to the amino-terminal region of the previously
described HIP1 [63]. This results in oligomerization and con-
stitutive activation of the kinase domain of PDGFRb, which
is suﬃcient to transform the hematopoietic cell line Ba/F3
[64]. Thus, the fusion of oligomerization domains of endo-
cytic adaptors to unrelated proteins as a consequence of
chromosomal translocations is an oncogenic mechanism, at
least in hematological malignancies.
Endocytic adaptors might also contribute by other mecha-
nisms to the transformation ability of fusion proteins. For
example, chimaeric proteins may display a dominant-negative
eﬀect on wild-type endocytic adaptors, thus impairing for in-
stance internalization and degradation of transmembrane
proteins well-known for their involvement in oncogenesis,
such as RTK. Though the proof-of-concept is missing, few
evidences suggest that this hypothesis might be true. CALM
(clathrin assembly myeloid lymphid leukemia) is a ubiqui-
tously expressed endocytic adaptor that was cloned as a fu-
sion partner of the transcription factor AF10 in acute
lymphoblastic leukemias and acute myeloid leukemias
[65,66]. CALM has high homology to the neuronal clath-
rin-adaptor protein AP3/AP180 and contains an amino-
terminal ANTH domain that binds to phosphatidyl-inositide
4,5-bis-phosphate as well as carboxyl-terminal binding sites
for clathrin and AP2. Interestingly, in the CALM-AF10 chi-
maeric protein the clathrin-binding region of CALM is
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CALM [67], thus impairing the formation of coated-pits
and vesicles. Another example exists in which sequestration
of clathrin by chimaeric proteins could be oncogenic. Large
anaplastic B-cell lymphomas often show constitutive activa-
tion of the Anaplastic Lymphoma Kinase (ALK) as a conse-
quence of chromosomal translocations that fuse it to various
partners. The translocation t(2;17)(p23;q23) fuses the ALK
kinase domain to almost all the clathrin heavy chain
(CLTC), including its trimerization domain. Oligomerization
of ALK-CLTC may result in constitutive activation of the
ALK kinase, similarly to the aforementioned PDGFRb-
HIP1. In addition it could bind to wild-type clathrin and
sequester it, providing a further oncogenic mechanism. How-
ever, experimental evidence for this hypothesis is required be-
fore any deﬁnite conclusion can be drawn. Fusions involving
endocytic proteins may be yet oncogenic via diﬀerent mech-
anisms. It is worthwhile to note that in the case of CAL-
MAF10 and MLL-AF10 fusions, deregulation of the
leucine-zipper domain of AF10 through the loss of inhibitory
control exerted by the PHD domain over it, has been recog-
nized as one oncogenic mechanism [68]. The EEN/endophilin
II gene was identiﬁed as a fusion partner of MLL in one
child with acute myelogenous leukemia [62]. The adaptor
EEN is a ubiquitous protein, with one SH3 domain similar
to the carboxyl-terminal SH3 domain of Grb2, and binds
to synaptojanin, dynamin and amphiphysins. Insight to the
functions of EEN has come from the recent identiﬁcation
of its binding partner EBP (EEN Binding Protein), which
also binds to Sos2, a guanine-nucleotide exchange factor
for Ras. Overexpression of EBP together with EEN sup-
presses Ras-induced cell transformation. It is likely that the
MLL-EEN fusion might sequester EBP in the nucleus, thus
blocking its Ras-suppressing function [69]. Future studies
should also investigate whether mutations of EEN that im-
pair binding to EBP are present in human malignancies.7. Conclusions
In the last few years, growing experimental evidence has
supported the notion that alterations in adaptor proteins re-
quired for receptor downregulation can be also oncogenic.
There are three pivotal mechanisms by which endocytic
adaptors contribute to cancer development. Firstly, lack-of-
function of endocytic adaptors that blocks proper receptor
sorting for degradation leads to quantitative changes in trans-
membrane receptor signaling. Secondly, mislocalized recep-
tors in diﬀerent cellular compartments can trigger aberrant
oncogenic signals. Lastly, a connection between endocytosis
and other cellular functions, notably gene transcription, is
established as a consequence of chromosomal translocations
that fuse endocytic adaptors to proteins normally unrelated
to endocytosis.
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